Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences to $76 from $68 and keeps a Hold rating on the shares. The analyst said he continues to stay on the sidelines until the company can show some meaningful improvement in TAVR, or until the TMTT business becomes sizable enough to offset the stagnation in TAVR.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
- Edwards Lifesciences sees Q1 adjusted EPS 58c-64c, consensus 59c
- Edwards Lifesciences backs FY23 adjusted EPS $2.45-$2.60, consensus $2.50
- Edwards Lifesciences reports Q4 adjusted EPS 64c, consensus 61c
- Edwards Lifesciences options imply 5.3% move in share price post-earnings